Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Preview: EASL 2015, what's left to say in hepatitis C?

This article was originally published in Scrip

Executive Summary

Analysts are expecting much less jubilation at this year's European Association for the Study of the Liver (EASL) International Liver Congress, due to start on April 22 in Vienna, Austria, compared with last year. Largely, this is because it is hard to improve on the near-100% cure rates seen with the new wave of hepatitis C therapies that were highlighted 12 months ago in London – specifically Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts